Goldman Sachs Group Inc Aravive, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	SELL	$1.25 - $1.92 $55,086 - $84,612	-44,069 Reduced 72.39%	16,809 $21,000
Q2 2023 Aug 14, 2023	SELL	$1.25 - $1.92 $55,086 - $84,612	-44,069 Reduced 72.39%	16,809 $21,000
Q1 2023 May 14, 2024	BUY	$1.29 - $2.46 $64,022 - $122,089	49,630 Added 441.23%	60,878 $121,000
Q1 2023 May 11, 2023	BUY	$1.29 - $2.46 $78,532 - $149,759	60,878 New	60,878 $121,000
Q2 2022 May 14, 2024	BUY	$0.93 - $1.9 $10,460 - $21,371	11,248 New	11,248 $11,000
Q2 2022 Aug 15, 2022	BUY	$0.93 - $1.9 $10,460 - $21,371	11,248 New	11,248 $11,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.